Netcapital Securities Assists Algernon NeuroScience in Regulation A Offering
Boston, MA, March 07, 2025 – Netcapital Inc. (NASDAQ: NCPL, NCPLW), a leading digital private capital markets ecosystem, has made an important announcement regarding its subsidiary, Netcapital Securities Inc. (“Netcapital Securities”), a FINRA-registered broker-dealer. The firm has been appointed by Algernon NeuroSciences Inc. (“Algernon NeuroSciences”) to provide broker-dealer and administrative services for its upcoming Regulation A (Reg A) offering.
Services to be Provided by Netcapital Securities
Netcapital Securities’ role in the offering includes facilitating the sale of securities to investors, managing communication with investors, and ensuring compliance with securities regulations. However, they will not be acting as underwriters or placement agents in this transaction.
Impact on Algernon NeuroSciences
Algernon NeuroSciences is a clinical-stage biopharmaceutical company focused on the development of therapeutics for neurodegenerative disorders. The Reg A offering is expected to provide the company with additional capital to further its research and development efforts. By partnering with Netcapital Securities, Algernon NeuroSciences can leverage the firm’s expertise in regulatory compliance and investor relations to ensure a successful offering.
Impact on the World
The collaboration between Netcapital Securities and Algernon NeuroSciences highlights the growing trend of digital capital markets platforms facilitating access to private offerings for a wider range of investors. This development could lead to increased investment opportunities for retail investors and smaller companies seeking capital. Furthermore, the success of this offering could encourage more companies in the biotech sector to explore Reg A as a funding option.
Conclusion
Netcapital Securities’ engagement by Algernon NeuroSciences for its Regulation A offering marks a significant milestone in the digital private capital markets ecosystem. By providing broker-dealer and administrative services, Netcapital Securities is helping to ensure a successful offering for Algernon NeuroSciences while contributing to the growing trend of increased investment opportunities for retail investors and smaller companies in the biotech sector.
- Netcapital Securities, a FINRA-registered broker-dealer and subsidiary of Netcapital Inc., has been appointed by Algernon NeuroSciences for its Regulation A offering.
- Netcapital Securities will provide broker-dealer and administrative services, excluding underwriting and placement agent services.
- Algernon NeuroSciences is a clinical-stage biopharmaceutical company focusing on neurodegenerative disorders.
- The Reg A offering is expected to provide additional capital for the company’s research and development efforts.
- The collaboration highlights the growing trend of digital capital markets platforms facilitating access to private offerings for retail investors and smaller companies.
